Which statement best describes differences between CGRP monoclonal antibodies and onabotulinumtoxinA in prevention?

Which statement best describes differences between CGRP monoclonal antibodies and onabotulinumtoxinA in prevention?

• A. CGRP monoclonal antibodies are injections at regular intervals; onabotulinumtoxinA is given every 12 weeks
• B. There are no differences
• C. CGRP monoclonal antibodies are taken orally; onabotulinumtoxinA is topical
• D. CGRP monoclonal antibodies are injections at regular intervals; onabotulinumtoxinA is given monthly

Answer: (A)

In migraine prevention, the key difference between CGRP monoclonal antibodies and onabotulinumtoxinA is how often and how they’re given. CGRP monoclonal antibodies are injections at regular intervals—most are administered as either monthly subcutaneous injections or quarterly infusions (depending on the agent). OnabotulinumtoxinA is an injectable treatment given by a clinician into specific head and neck muscles every 12 weeks. So the statement that CGRP monoclonal antibodies are injections at regular intervals and onabotulinumtoxinA is given every 12 weeks best captures the practical differences.

In migraine prevention, the key difference between CGRP monoclonal antibodies and onabotulinumtoxinA is how often and how they’re given. CGRP monoclonal antibodies are injections at regular intervals—most are administered as either monthly subcutaneous injections or quarterly infusions (depending on the agent). OnabotulinumtoxinA is an injectable treatment given by a clinician into specific head and neck muscles every 12 weeks. So the statement that CGRP monoclonal antibodies are injections at regular intervals and onabotulinumtoxinA is given every 12 weeks best captures the practical differences.